TrovaGene Inc (TROV)

0.81
NASDAQ : Health Care
Prev Close 0.81
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.61 / 5.76
Avg Volume 957.60K
Exchange NASDAQ
Shares Outstanding 37.27M
Market Cap 31.31M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Trovagene Announces FDA Approval Of IND For Phase 1b/2 Trial Of PCM-075 In Patients With Acute Myeloid Leukemia

Trovagene Announces FDA Approval Of IND For Phase 1b/2 Trial Of PCM-075 In Patients With Acute Myeloid Leukemia

PCM-075, in combination with decitabine, in patients with Acute Myeloid Leukemia (AML) for exploration of the safety, tolerability, dose and scheduling, and antitumor activity

Trovagene Announces Peer-Reviewed Publication Of First-in-Human Phase 1 Trial Results With PCM-075, Its Polo-like Kinase 1 (PLK1) Inhibitor

Trovagene Announces Peer-Reviewed Publication Of First-in-Human Phase 1 Trial Results With PCM-075, Its Polo-like Kinase 1 (PLK1) Inhibitor

Greater selectivity for PLK1, potency, oral bioavailability and short half-life underscore PCM-075's potential as safe and effective treatment for solid tumor and hematological malignancies

Short Interest Expands By 14.2% For TROV

The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 442,930 share increase in total short interest for TrovaGene Inc , to 3,567,833, an increase of 14.17% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Phase 1 Safety Study Supports Planned Development Of PCM-075 In AML

Study evaluated safety, dose limiting toxicities, related maximum tolerated dose and indication of anti-tumor activity in patients with advanced or metastatic solid tumors

Short Interest Moves 16.3% Higher For TROV

The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 460,990 share increase in total short interest for TrovaGene Inc , to 3,292,918, an increase of 16.28% since 04/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Trovera™ EGFR Urine Liquid Biopsy Test Predictive Of Clinical Response To Therapy: Case Series In Patients With Non-Small Cell Lung Cancer

Authors conclude that ctDNA testing demonstrates clinical utility in assessing disease burden and response to therapy

TrovaGene (TROV) Is Today's Strong On High Volume Stock

TrovaGene (TROV) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified TrovaGene (TROV) as a strong on high relative volume candidate

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Trovagene, Inc. - TROV

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Trovagene, Inc. - TROV

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Trovagene, Inc.

Short Interest Jumps 17.6% For TROV

Short Interest Jumps 17.6% For TROV

The most recent short interest data has been released by the NASDAQ for the 02/12/2016 settlement date, which shows a 697,508 share increase in total short interest for TrovaGene Inc , to 4,657,297, an increase of 17.61% since 01/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.